United States

Repros Therapeutics Inc (RPRX.OQ)

RPRX.OQ on NASDAQ Stock Exchange Capital Market

4:00pm EDT
Change (% chg)

$0.02 (+1.94%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Select another date:

Mon, Apr 10 2017

BRIEF-Repros Therapeutics meets with FDA to discuss Proellex in treatment of uterine fibroids

* Company holds meeting with FDA to discuss oral Proellex® in the treatment of uterine fibroids

BRIEF-Repros names Larry Dillaha M.D. its permanent president and CEO

* Repros names Larry Dillaha, M.D., its permanent president and ceo

BRIEF-Repros Therapeutics Inc reports • Q4 loss per share $0.16

* Repros Therapeutics Inc reports fourth quarter and year end 2016 financial results

BRIEF-Repros announces new CEO

* Larry Dillaha was appointed interim president and chief executive officer of company, effective immediately Source text for Eikon: Further company coverage:

BRIEF-Repros Therapeutics reports loss per share of $0.17

* Repros Therapeutics In Reports third quarter 2016 financial results

Select another date:

More From Around the Web